Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261

Tony Johnson, M.D.

President and CEO of Goldfinch Bio

Dr. Tony Johnson joined Goldfinch Bio as president and chief executive officer in 2017. He brings 25 years of academic, industry and venture experience including several years in R&D senior leadership roles. Prior to Goldfinch Bio, Tony was head of early clinical development and chief medical officer of the Innovative Medicines and Early Development Biotech Unit at AstraZeneca, and a Fellow at Homerton College, Cambridge, U.K.

This role was preceded by experience as a venture partner at OrbiMed Advisors and industry positions as vice president, discovery medicine and clinical pharmacology with Bristol-Myers Squibb, vice president, discovery medicine at GlaxoSmithKline and founding director of the GlaxoWelcome Medicines Research Unit. He was a tenured academic at the University of Queensland, Australia prior to his industry experience. Tony received his medical training (M.B.B.S.) and research doctorate (M.D.) at the University of New South Wales and his M.P.H. from the University of Queensland.

He is a Fellow of the Royal Australasian College of Physicians and is board certified in internal medicine, geriatric medicine and clinical pharmacology. Prior training included the Rowden White Fellowship (Boston, U.S.) and time as a visiting academic scholar (Cambridge, U.K.). Tony was a Board Director for Cardioxyl until acquired by BMS and a Board Observer for Rgenix until he joined AstraZeneca, continuing on their Clinical Advisory Board. He has had 18 years of broad clinical practice.